US FDA slow in debarring clinical investigators convicted of wrongdoings
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration fails to debar quickly enough clinical investigators convicted of contravening medical product regulations from engaging in research, according to a Government Accountability Office report1.